Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo

References

• Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-77; PMID:8336186
   PubMed Web of Science ®Google Scholar
• Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17:2264-79; PMID:10561284
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203-16; PMID:12612655; http://dx.doi.org/10.1038/nrc1014
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369:2106-20; PMID:17586306; http://dx.doi.org/10.1016/S0140-6736(07)60983-0
   PubMed Web of Science ®Google Scholar
• Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54; PMID:8441429; http://dx.doi.org/10.1056/NEJM199303253281205
   PubMed Web of Science ®Google Scholar
• Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, Spengler BA, Lucarelli E, Bates SE, Thiele CJ. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 1996; 56:3737-42; PMID:8706017
   PubMed Web of Science ®Google Scholar
• Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res 2002; 62:6756-63; PMID:12438277
   PubMed Web of Science ®Google Scholar
• Li Z, Oh DY, Nakamura K, Thiele CJ. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer 2011; 117:5412-22; PMID:21590687; http://dx.doi.org/; http://dx.doi.org/10.1002/cncr.26133
   PubMed Web of Science ®Google Scholar
• Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res 2005; 65:2070-5; PMID:15781614; http://dx.doi.org/10.1158/0008-5472.CAN-04-3606
   PubMed Web of Science ®Google Scholar
• Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt Vv, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005; 228:143-53; PMID:15921851; http://dx.doi.org/10.1016/j.canlet.2005.02.051
   PubMed Web of Science ®Google Scholar
• Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14:759-67; PMID:8264643
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995; 55:1798-806; PMID:7712490
   PubMed Web of Science ®Google Scholar
• Norris RE, Minturn JE, Brodeur GM, Maris JM, Adamson PC. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemother Pharmacol 2011; 68:1469-75; PMID:21484309; http://dx.doi.org/10.1007/s00280-011-1623-y
   PubMed Web of Science ®Google Scholar
• Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer 2011; 117:1321-91; PMID:20960503; http://dx.doi.org/10.1002/cncr.25674
   PubMed Web of Science ®Google Scholar
• Iyer R, Varela CR, Minturn JE, Ho R, Simpson AM, Light JE, Evans AE, Zhao H, Thress K, Brown JL, et al. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemother Pharmacol 2012; 70:477-86; PMID:22623209; http://dx.doi.org/10.1007/s00280-012-1879-x
   PubMed Web of Science ®Google Scholar
• Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 1999; 5:2205-12; PMID:10473107
   PubMed Web of Science ®Google Scholar
• Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 2001; 7:2237-45; PMID:11489797
   PubMed Web of Science ®Google Scholar
• Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003; 63:5559-63; PMID:14500395
   PubMed Web of Science ®Google Scholar
• Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs 2010; 19:427-36; PMID:20141349; http://dx.doi.org/10.1517/13543781003598862
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103:3669-76; PMID:14726387; http://dx.doi.org/10.1182/blood-2003-11-3775
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111:5663-71; PMID:17984313; http://dx.doi.org/10.1182/blood-2007-04-083402
   PubMed Web of Science ®Google Scholar
• Grade S, Weng YC, Snapyan M, Kriz J, Malva JO, Saghatelyan A. Brain-derived neurotrophic factor promotes vasculature-associated migration of neuronal precursors toward the ischemic striatum. PLoS One 2013; 8:e55039; PMID:23383048; http://dx.doi.org/10.1371/journal.pone.0055039
   PubMedGoogle Scholar